Congratulations Mohammad Jad Moussa, MD, MSc Omar Alhalabi, MD Matt Campbell MD, MS & the MD Anderson Cancer Center team! Thank you for linking our Rare Tumors review.

Thank you Dr. Jain and @DAVAonc for the opportunity to discuss the role of maintenance avelumab in advanced urothelial carcinoma. Identifying patient preferences (balancing survival and quality of life) may help in pairing the right individual with the right regimen.

Announcing #SoCalGU25, which will be held on February 28, 2025. This consortium of GU #oncology investigators bridges efforts from City of Hope, UC Irvine, UCLA Jonsson Comprehensive Cancer Center, Cancer at Cedars-Sinai, UC San Diego Health Moores Cancer Center, USC Norris Comprehensive Cancer Center & other #SoCal institutions. Last year, our registration filled

Amazing piece of work by David J. Benjamin, MD, Rana McKay, MD, FASCO and colls. with impact in daily practice: urachal tumors approach should be based on colorrectal cancer schemes rather than bladder. I would love to see insights of activity of EV or ICIs in this scenario vs FOLFOX or

Why did sacituzumab govitecan fail in the TROPiCS-04 study for advanced urothelial carcinoma? In European Urology Oncology, we discuss the potential roles of G-CSF, dosing approaches, and differences in patient population compared to the TROPHY-U-01 trial. Link: authors.elsevier.com/a/1kUbL9Cfw03R…

Looking forward to reviewing this editorial. Timely since TROPiCS04 paper coming very soon, stay tuned :-) Tom Powles Uromigos Yohann Loriot Scott Tagawa joaquim bellmunt Cora Sternberg Bladder Cancer Advocacy Network Joshua Meeks Sumanta K. Pal, MD, FASCO Brian Rini, MD Shilpa Gupta Andrea Apolo, M.D. Abhishek Tripathi OncoAlert

Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians Syed A Hussain Ravindran Kanesvaran 💙alison birtle David J. Benjamin, MD Patrizia Giannatempo OncoAlert - Cancer Treatment Reviews cancertreatmentreviews.com/article/S0305-…

2024 State of the GU Med Onc workforce in 🇺🇸David J. Benjamin, MD UroToday.com #GU25 🔊Used the Top 50 hospitals/state per U.S. News & World Report to identify GU predominant Med Oncs 🔊n=451, 88.5% academic 🔊72.5% male, 3.8% URiM 🔊28.8% trained outside of 🇺🇸 🔊7 states, no GU Med Onc

State of the Genitourinary Medical Oncology Workforce in the United States, 2024. Presentation by David J. Benjamin, MD Hoag. #GU25 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/4k1Mqtd ASCO

Does reading an article about a public figure with cancer leave you with more uncertainty than clarity? In ESMO - Eur. Oncology Real World Data and Digital Oncology, we review news articles about public figures with cancer from 2010 to 2020. Our study found that most articles lack pertinent

Our paper is out: I found this interesting Some cancers celebs are more likely to admit to having than others. Above the line is over represented reporting in media.

One of the highlights of #SoCalGU25 was our inaugural poster session. Congrats to our poster sessions winners, #DrFarzadTeymouri, Nikko Gonzales & Mazyar (Menachem) Zahir, M.D. - equally deserving are their mentors Arash Rezazadeh UC Irvine, David J. Benjamin, MD Hoag, Edwin Posadas, MD,

How many genitourinary medical oncologists are in the US, and where (region, practice setting, etc.) do they practice? In Urology Gold Journal, we find that there are a total of 451 GU medical oncologists in the US, most of whom are men (72.5%). The majority of GU medical

🧨Great to be editors pick in The Lancet Oncology this month for our comment....highlighting Sexual health and reproductive toxicity from cancer therapies thelancet.com/journals/lanon… David J. Benjamin, MD Surgery and Cancer Ash Paul Richard Sullivan Bishal Gyawali, MD, PhD, FASCO Dario Trapani Dr Amol Akhade BMJ Oncology

Is the field of oncology overlooking sexual health and reproductive toxicities from cancer therapies? In The Lancet Oncology, Dr Mark Lythgoe and I highlight two recent examples, and call for improved monitoring & reporting in clinical trials. Many thanks to the editorial team for

The Lancet Oncology Comment: As cancer therapies evolve, sexual & reproductive #Toxicity remains underreported. Experts like David J. Benjamin, MD call for integrating #Oncofertility into routine care—especially for younger patients. bit.ly/4lwGBET #ReproductiveHealth

Congratulations to my mentor Arash Rezazadeh on receiving the 2025 UC Irvine School of Medicine Faculty Mentor of the Year Award! There is no more deserving individual I know who mentors faculty and trainees across multiple specialities and institutions. Fortunate and grateful for your

RWE is crucial for our daily clinical practice! What insightful discussions on mUC treatments! Balancing QoL with efficacy is the key! Enrique Grande David J. Benjamin, MD